182 related articles for article (PubMed ID: 8216374)
1. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
Los G; van Vugt MJ; den Engelse L; Pinedo HM
Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374
[TBL] [Abstract][Full Text] [Related]
2. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
Los G; Verdegaal E; Noteborn HP; Ruevekamp M; de Graeff A; Meesters EW; ten Bokkel Huinink D; McVie JG
Biochem Pharmacol; 1991 Jul; 42(2):357-63. PubMed ID: 1859450
[TBL] [Abstract][Full Text] [Related]
3. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
Los G; van Vugt MJ; Pinedo HM
Br J Cancer; 1994 Feb; 69(2):235-41. PubMed ID: 8297720
[TBL] [Abstract][Full Text] [Related]
4. Effect of ultrafilterable platinum concentration on cisplatin and carboplatin cytotoxicity in human tumor and bone marrow cells in vitro.
Guchelaar HJ; de Vries EG; Meijer C; Esselink MT; Vellenga E; Uges DR; Mulder NH
Pharm Res; 1994 Sep; 11(9):1265-9. PubMed ID: 7816754
[TBL] [Abstract][Full Text] [Related]
5. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
6. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
7. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
Los G; Tuyt L; van Vugt M; Schornagel J; Pinedo HM
Cancer Chemother Pharmacol; 1993; 32(6):425-33. PubMed ID: 8258189
[TBL] [Abstract][Full Text] [Related]
9. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion?
Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; van der Velde-Visser SD; Berends F; Baan RA
Carcinogenesis; 1995 Oct; 16(10):2447-53. PubMed ID: 7586150
[TBL] [Abstract][Full Text] [Related]
12. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
Treskes M; Nijtmans LG; Fichtinger-Schepman AM; van der Vijgh WJ
Biochem Pharmacol; 1992 Mar; 43(5):1013-9. PubMed ID: 1313234
[TBL] [Abstract][Full Text] [Related]
13. [Cytokinetic effects of carboplatin and cisplatin on a human ovarian cancer cell line].
Yoshizumi N; Fujiwara J; Yoshizaki A; Sato M; Sakai R; Nishiya I
Hum Cell; 1988 Sep; 1(3):301-7. PubMed ID: 2979207
[TBL] [Abstract][Full Text] [Related]
14. Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
Vaden SL; Williams PL; Page RL; Riviere JE
Cancer Chemother Pharmacol; 1993; 32(1):31-8. PubMed ID: 8462121
[TBL] [Abstract][Full Text] [Related]
15. [Probability of the combination use of cisplatin and carboplatin].
Kobayashi K; Hino M; Hayashihara K; Niitani H
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2684-92. PubMed ID: 2277219
[TBL] [Abstract][Full Text] [Related]
16. Enhanced formation of reactive species from cis-diammine-(1,1-cyclobutanedicarboxylato)-platinum(II) (carboplatin) in the presence of oxygen free radicals.
Tonetti M; Giovine M; Gasparini A; Benatti U; De Flora A
Biochem Pharmacol; 1993 Oct; 46(8):1377-83. PubMed ID: 8240386
[TBL] [Abstract][Full Text] [Related]
17. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
[TBL] [Abstract][Full Text] [Related]
18. Similar effects of cis-diamminedichloroplatinum(II) and cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II) on sodium-coupled glucose uptake in renal brush-border membrane vesicles.
Potdevin S; Courjault-Gautier F; Ripoche P; Toutain HJ
Arch Toxicol; 1998 Oct; 72(10):663-70. PubMed ID: 9851683
[TBL] [Abstract][Full Text] [Related]
19. Platinum complex-induced dysfunction of cultured renal proximal tubule cells. A comparative study of carboplatin and transplatin with cisplatin.
Courjault F; Leroy D; Coquery L; Toutain H
Arch Toxicol; 1993; 67(5):338-46. PubMed ID: 8396390
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
Misawa T; Kikkawa F; Maeda O; Obata NH; Higashide K; Suganuma N; Tomoda Y
Jpn J Cancer Res; 1995 Jan; 86(1):88-94. PubMed ID: 7737915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]